The global SGLT-2 Inhibitors Market is projected to experience significant revenue growth over the forecast period, driven by the increasing prevalence of diabetes mellitus worldwide. According to the World Health Organization (WHO), the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014, with a particularly rapid increase in low- and middle-income countries. The mortality rate from diabetes has also been on the rise, with an estimated 1.5 million deaths attributed directly to diabetes in 2019, making it the ninth leading cause of death globally.

Type 2 diabetes, which affects over 95% of patients with diabetes, is primarily caused by improper insulin use due to factors such as being overweight and leading a sedentary lifestyle with minimal physical activity. This has contributed to the expansion of the market for SGLT-2 inhibitors as an effective treatment option.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5343

SGLT-2 inhibitors are a class of oral anti-hyperglycemic medications that have received FDA approval for the treatment of diabetes mellitus. These prescription drugs, including canagliflozin, dapagliflozin, and empagliflozin, work by reducing blood sugar levels in patients with type 2 diabetes when used in conjunction with diet and exercise. They have a unique mechanism of action, stimulating insulin secretion and increasing the excretion of sugar by the kidneys.

There are several driving factors behind the growth of the global SGLT-2 inhibitors market. The burden and severity of diabetes mellitus have been increasing over the past three decades, with an estimated 6.28% of the world's population, or 462 million people, having type 2 diabetes in 2017. This high prevalence, coupled with significant lifestyle changes, unhealthy dietary practices, and increased rates of obesity, has led to a greater incidence of diabetes, thereby boosting the demand for SGLT-2 inhibitors.

Moreover, increased investment in research and development by key stakeholders and advancements in technology have facilitated the development of novel therapeutic alternatives for managing diabetes. Government efforts to raise awareness about the disease and campaigns offering free blood tests, along with the availability of wearable devices, have contributed to early diagnosis rates. Additionally, improved healthcare facilities and higher healthcare spending are expected to support the expansion of the SGLT-2 inhibitors market.

However, the market faces some restraints. Biguanide, sulfonylureas, and DPP-4 inhibitors are the most commonly used drug classes for diabetes treatment and may limit the growth of SGLT-2 inhibitors. Additionally, the availability of generic SGLT-2 inhibitors is relatively limited compared to other drug classes.

Despite these challenges, there are significant opportunities for the global SGLT-2 inhibitors market. The rising prevalence of diabetes mellitus presents a favorable market landscape. Ongoing clinical trials and increased research and development efforts have paved the way for the introduction of innovative compounds like dapagliflozin and empagliflozin, which hold promise as groundbreaking treatments.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/5343

Geographically, North America, particularly the United States, is expected to dominate the market, driven by the high prevalence of diabetes in the region. According to the National Diabetes Statistics Report for 2020, over 34.2 million Americans have diabetes, with 90-95% of them having type 2 diabetes. The market growth in North America is supported by enhanced research and development efforts, technological advancements, the presence of major companies, increased acceptance of innovative treatments, improved healthcare infrastructure, and greater public awareness.

The Asia Pacific region is anticipated to witness the fastest growth during the forecast period. Factors such as a large patient pool, high prevalence of diabetes, rising disposable income, increased public awareness, improved healthcare infrastructure, and growing research and development activities contribute to this growth. Countries like China, South Korea, Australia, and India are expected to drive market expansion in the region.

In terms of market trends and innovation, SGLT-2 inhibitors have emerged as a dominant class of anti-hyperglycemic medications due to their unique mechanism of action. Jardiance, developed by Boehringer Ingelheim, leads the market with its lower cardiovascular risk and superior blood sugar-lowering efficacy compared to other SGLT-2 drugs. Ongoing efforts in organic and inorganic strategies, such as gaining additional FDA approvals for new indications, have further strengthened the market presence of key players like AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Pfizer.

To provide a comprehensive understanding of the market, our report includes historical data, forecasts, and revenue growth at a global, regional, and country level. It offers detailed analysis of industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and the contribution of each regional and country market. Additionally, the report covers industry analysis, competitive landscape, company financials, and impact analysis.

Overall, the global SGLT-2 inhibitors market is poised for significant growth due to the increasing prevalence of diabetes mellitus. The development of innovative treatments and expanding research efforts are expected to drive market expansion, with North America and the Asia Pacific region being the key markets to watch.

Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5343

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

Browse for more reports:

https://www.reportsanddata.com/report-detail/cell-surface-markers-market

https://www.reportsanddata.com/report-detail/cosmetic-dentistry-market

https://www.reportsanddata.com/report-detail/apheresis-equipment-market

https://www.reportsanddata.com/report-detail/dental-x-ray-market

https://www.reportsanddata.com/report-detail/cartilage-repair-market

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report